F7 (coagulation factor VII) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Gene: F7 (coagulation factor VII) Rattus norvegicus
Analyze
Symbol: F7
Name: coagulation factor VII
RGD ID: 628678
Description: Enables endopeptidase activity and signaling receptor binding activity. Involved in several processes, including response to cholesterol; response to peptide hormone; and response to thyroxine. Located in extracellular space and vesicle. Used to study asthma; diabetes mellitus; and type 2 diabetes mellitus. Biomarker of several diseases, including bilirubin metabolic disorder; familial hyperlipidemia; hypertension; hypothyroidism; and prothrombin deficiency. Human ortholog(s) of this gene implicated in several diseases, including artery disease (multiple); cerebral infarction; diabetes mellitus (multiple); factor VII deficiency; and obesity. Orthologous to human F7 (coagulation factor VII); PARTICIPATES IN coagulation cascade pathway; acenocoumarol pharmacodynamics pathway; alteplase pharmacodynamics pathway; INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; acenocoumarol.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: coagulation factor VII (serum prothrombin conversion accelerator); serum prothrombin conversion accelerator
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81683,191,896 - 83,202,775 (-)NCBIGRCr8
mRatBN7.21676,489,775 - 76,500,636 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1676,489,717 - 76,500,610 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1681,770,823 - 81,781,136 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01685,223,400 - 85,233,713 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01680,472,689 - 80,483,066 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01681,824,610 - 81,834,923 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1681,824,111 - 81,834,945 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01681,309,476 - 81,320,833 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41681,348,678 - 81,358,991 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11681,348,942 - 81,359,256 (-)NCBI
Celera1674,296,307 - 74,306,282 (-)NCBICelera
Cytogenetic Map16q12.5NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acquired angioedema  (ISO)
Acute Liver Failure  (ISO)
acute pancreatitis  (ISO)
Acute Subdural Hematoma  (ISO)
Albuminuria  (ISO)
Animal Disease Models  (ISO)
Arterial Thrombosis  (IMP,ISO)
arteriosclerosis  (ISO)
asthma  (IDA)
bilirubin metabolic disorder  (IEP)
blood coagulation disease  (ISO)
breast cancer  (ISO)
Cerebral Hemorrhage  (ISO)
cerebral infarction  (ISO)
Choroidal Neovascularization  (ISO)
Chronic Allograft Dysfunction  (ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (ISO)
coronary artery disease  (ISO)
diabetes mellitus  (IDA,IEP,ISO)
diabetic neuropathy  (ISO)
diabetic retinopathy  (ISO)
disseminated intravascular coagulation  (ISO)
Endotoxemia  (IEP,ISO)
Experimental Diabetes Mellitus  (IDA,IEP)
Extrahepatic Portal Vein Obstruction  (IEP)
factor VII deficiency  (ISO)
factor VIII deficiency  (ISO)
factor X deficiency  (ISO)
familial hyperlipidemia  (IEP)
genetic disease  (ISO)
Glandular and Epithelial Neoplasms  (IEP)
Hematuria  (ISO)
Hemorrhage  (ISO)
hemorrhagic disease  (ISO)
hereditary angioedema  (ISO)
hyperglycemia  (ISO)
hypertension  (IEP,ISO)
Hypertriglyceridemia  (ISO)
hypothyroidism  (IEP)
Inherited Blood Coagulation Disease  (ISO)
Insulin Resistance  (ISO)
intermediate coronary syndrome  (ISO)
Intestinal Reperfusion Injury  (ISO)
Intracranial Hemorrhages  (ISO)
kidney disease  (ISO)
myocardial infarction  (ISO)
obesity  (ISO)
ovarian cancer  (ISO)
Postoperative Complications  (ISO)
proteinuria  (ISO)
prothrombin deficiency  (IEP)
Sepsis  (IDA,IEP)
Smoke Inhalation Injury  (IEP)
Stable Angina  (ISO)
thrombocytopenia  (ISO)
Thromboembolism  (ISO)
Traumatic Intracranial Hemorrhage  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (IDA,ISO)
Venous Thrombosis  (IMP,ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-schisandrin B  (EXP)
(1->4)-beta-D-glucan  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (EXP,ISO)
2,3,7,8-tetrachlorodibenzodioxine  (ISO)
4,4'-sulfonyldiphenol  (ISO)
acenocoumarol  (EXP)
acetamide  (EXP)
aflatoxin B1  (ISO)
Aflatoxin B2 alpha  (ISO)
aldehydo-D-glucose  (ISO)
aldrin  (ISO)
ammonium chloride  (EXP)
aspalathin  (ISO)
benzo[a]pyrene  (ISO)
benzo[e]pyrene  (ISO)
bisphenol A  (EXP,ISO)
butanal  (ISO)
cadmium dichloride  (EXP)
carbon nanotube  (ISO)
chlorpyrifos  (ISO)
clofibrate  (ISO)
cyclosporin A  (ISO)
D-glucose  (ISO)
dexamethasone  (ISO)
dienogest  (ISO)
Difethialone  (EXP)
doxorubicin  (ISO)
epoxiconazole  (ISO)
Ethyl icosapentate  (EXP)
ethylparaben  (ISO)
fenofibrate  (ISO)
fenthion  (ISO)
folic acid  (ISO)
fructose  (ISO)
fumonisin B1  (ISO)
furan  (EXP)
gemcitabine  (ISO)
geneticin  (ISO)
genistein  (EXP)
gestodene  (ISO)
glucose  (ISO)
graphite  (EXP)
hexestrol  (EXP)
hydrogen peroxide  (ISO)
levonorgestrel  (ISO)
medroxyprogesterone acetate  (ISO)
menaquinone  (EXP)
mestranol  (ISO)
methapyrilene  (ISO)
methidathion  (ISO)
morphine  (ISO)
N-Nitrosopyrrolidine  (ISO)
norethisterone  (ISO)
norgestimate  (ISO)
O-methyleugenol  (ISO)
ozone  (ISO)
paracetamol  (ISO)
pentanal  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
phenobarbital  (EXP)
phenprocoumon  (EXP)
pirinixic acid  (ISO)
propanal  (ISO)
quercetin  (ISO)
riddelliine  (EXP)
silicon dioxide  (ISO)
sodium arsenite  (ISO)
sulforaphane  (ISO)
tamoxifen  (ISO)
tetrachloromethane  (EXP,ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
trichloroethene  (EXP)
trimellitic anhydride  (ISO)
trovafloxacin  (ISO)
urethane  (ISO)
valproic acid  (ISO)
warfarin  (EXP,ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

References

References - curated
# Reference Title Reference Citation
1. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Al-Obaidi MK, etal., Circulation. 2000 Feb 1;101(4):372-7.
2. Experimental gram-negative septicemia: thromboplastin generation in mononuclear phagocytes from different anatomical sites. Almdahl SM and Osterud B, Thromb Res. 1987 Jul 1;47(1):37-46.
3. Activity of factor VIIa and von Willebrand factor in non-insulin-dependent diabetic subjects with coronary artery disease. Altinbas A, etal., J Int Med Res. 1999 Jul-Aug;27(4):185-90.
4. Treatment with anti-factor VIIa in acute pancreatitis in rats: blocking both coagulation and inflammation? Andersson E, etal., Scand J Gastroenterol. 2007 Jun;42(6):765-70.
5. The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor. Arnold CS, etal., Thromb Res. 2006;117(3):343-9.
6. Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Aronson D, etal., Am J Cardiol. 1999 Aug 15;84(4):449-53.
7. Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients. Avellone G, etal., Metabolism. 1997 Aug;46(8):930-4.
8. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Bavenholm P, etal., Thromb Haemost. 1995 Apr;73(4):568-75.
9. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. Boden G, etal., J Clin Endocrinol Metab. 2007 Nov;92(11):4352-8. Epub 2007 Sep 4.
10. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats. Bouwman CA, etal., Chemosphere. 1999 Feb;38(3):489-505.
11. Blood glucose may condition factor VII levels in diabetic and normal subjects. Ceriello A, etal., Diabetologia. 1988 Dec;31(12):889-91.
12. Anticoagulatory and antiinflammatory effects of astaxanthin in diabetic rats. Chan KC, etal., J Food Sci. 2012 Feb;77(2):H76-80. doi: 10.1111/j.1750-3841.2011.02558.x. Epub 2012 Feb 6.
13. Expression of MRP2 and MRP3 during liver regeneration after 90% partial hepatectomy in rats. Chang TH, etal., Transplantation 2004 Jan 15;77(1):22-7.
14. Factor VII transcription correlates with hepatocyte proliferation and hepatocyte growth factor expression in a rodent extrahepatic portal vein obstruction model. Chiu B, etal., J Am Coll Surg. 2007 Aug;205(2):277-83.
15. Effect of abdominal obesity on prothrombotic tendency in type 2 diabetes. Behavior of clotting factors VII and VIII, fibrinogen and von Willebrand Factor. Coca M, etal., Rom J Intern Med. 2005;43(1-2):115-26.
16. Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. Cornu C, etal., Maturitas. 2000 Dec 29;37(2):95-104.
17. Activation of the coagulation cascade in C1-inhibitor deficiencies. Cugno M, etal., Blood. 1997 May 1;89(9):3213-8.
18. Fibrinogen and factor VII levels improve with glycemic control in patients with type 1 diabetes mellitus who have microvascular complications. D'Elia JA, etal., Arch Intern Med. 2001 Jan 8;161(1):98-101.
19. Risk factors for thromboembolic events in renal failure. D'Elia JA, etal., Int J Cardiol. 2005 May 11;101(1):19-25.
20. Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. Darko DA, etal., Diabetes Res Clin Pract. 2001 Dec;54(3):157-64.
21. Alcohol-free red wine prevents arterial thrombosis in dietary-induced hypercholesterolemic rats: experimental support for the 'French paradox'. De Curtis A, etal., J Thromb Haemost. 2005 Feb;3(2):346-50.
22. Experimental arterial thrombosis in genetically or diet induced hyperlipidemia in rats--role of vitamin K-dependent clotting factors and prevention by low-intensity oral anticoagulation. De Curtis A, etal., Thromb Haemost. 2001 Dec;86(6):1440-8.
23. The effect of microalbuminuria on glycaemic control, serum lipids and haemostasis parameters in non-insulin-dependent diabetes mellitus. Donders SH, etal., Ann Clin Biochem. 1993 Sep;30 ( Pt 5):439-44.
24. Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model. Dong F, etal., Evid Based Complement Alternat Med. 2014;2014:726740. doi: 10.1155/2014/726740. Epub 2014 Jan 2.
25. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Duncan BB, etal., Diabetes Care. 1999 May;22(5):767-72.
26. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Erem C, etal., Med Princ Pract. 2005 Jan-Feb;14(1):22-30.
27. Disturbances of haemostasis in diabetes mellitus. Fattah MA, etal., Dis Markers. 2003-2004;19(6):251-8.
28. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Ford I, etal., Metabolism. 2001 Aug;50(8):868-75.
29. Haemostatic variables associated with diabetes and its complications. Fuller JH, etal., Br Med J. 1979 Oct 20;2(6196):964-6.
30. Localization of factor VII (proconvertin) in a microsomal subfraction. Gaarder A and Prydz H, Biochim Biophys Acta. 1969 Jun 17;184(1):220-3.
31. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
32. Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. Gentile NT, etal., Thromb Haemost. 2007 Nov;98(5):1007-13.
33. Anti-thrombotic and haemorrhagic effects of active site-inhibited factor VIIa in rats. Ghrib F, etal., Br J Haematol. 2001 Feb;112(2):506-12.
34. Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients. Giusti C, etal., Br J Ophthalmol. 2000 Jun;84(6):591-5.
35. The inhibitors of the tissue factor:factor VII pathway. Golino P Thromb Res. 2002 May 1;106(3):V257-65.
36. A novel gene insertion combined with a missense mutation causing factor VII deficiency in two unrelated Chinese families. Hao X, etal., Blood Coagul Fibrinolysis. 2015 Sep;26(6):687-90. doi: 10.1097/MBC.0000000000000319.
37. Vitamin K-dependent blood clotting changes in female rats treated with oestrogens. Hart JE Thromb Haemost. 1987 Jun 3;57(3):273-7.
38. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Hirano T, etal., Diabetes Res Clin Pract. 1997 Apr;36(1):11-8.
39. Hemostatic risk factors of coronary artery disease in the Chinese. Ho CH, etal., Int J Cardiol. 1995 Aug;51(1):79-84.
40. Role of coagulation factor VII in pathogenesis of ischemic heart disease. Hu Y, etal., J Huazhong Univ Sci Technolog Med Sci. 2006;26(6):657-60.
41. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. Iacoviello L, etal., N Engl J Med. 1998 Jan 8;338(2):79-85.
42. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. Jastrzebska M, etal., Int J Clin Pharmacol Res. 1999;19(1):19-25.
43. Polymorphisms of the coagulation factor VII gene and its plasma levels in relation to acute cerebral infarction differences in allelic frequencies between Chinese Han and European populations. Kang WY, etal., Chin Med J (Engl). 2004 Jan;117(1):71-4.
44. Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2). Karatela RA and Sainani GS, Diabetes Res Clin Pract. 2009 Jun;84(3):e41-4. Epub 2009 Mar 28.
45. Early hemostatic therapy using recombinant factor VIIa in a collagenase-induced intracerebral hemorrhage model in rats. Kawai N, etal., Acta Neurochir Suppl. 2006;96:212-7.
46. Genistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens. Kelly LA, etal., Thromb Haemost. 2010 Sep 13;104(6).
47. Hyperlipidemia, hypercoagulability, and accelerated thrombosis: studies in congenitally hyperlipidemic rats and in rats and monkeys with induced hyperlipidemia. Kim WM, etal., Blood. 1976 Feb;47(2):275-86.
48. Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases. Koizume S, etal., Mol Cancer Res. 2009 Dec;7(12):1928-36. doi: 10.1158/1541-7786.MCR-09-0372. Epub 2009 Dec 8.
49. Genetic influence of the R/Q353 genotype on factor VII activity is overwhelmed by environmental factors in Chinese patients with Type II (non-insulin-dependent) diabetes mellitus. Lam KS, etal., Diabetologia. 1998 Jul;41(7):760-6.
50. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Laudes IJ, etal., Am J Pathol. 2002 May;160(5):1867-75.
51. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. Lauritzen B, etal., J Thromb Haemost. 2009 Apr;7(4):651-7. doi: 10.1111/j.1538-7836.2009.03287.x. Epub 2009 Jan 19.
52. Prothrombotic and antithrombotic factors are elevated in patients with type 1 diabetes complicated by microalbuminuria. Lee P, etal., Diabet Med. 1993 Mar;10(2):122-8.
53. Association between the factor VII haplotype containing the -402A allele and myocardial infarction in a population of elderly men at high risk for coronary heart disease. Lindman AS, etal., Thromb Haemost. 2005 Jul;94(1):226-7.
54. Consumption of a controlled low-fat diet containing olestra for 9 months improves health risk factors in conjunction with weight loss in obese men: the Ole' Study. Lovejoy JC, etal., Int J Obes Relat Metab Disord. 2003 Oct;27(10):1242-9.
55. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. Lu F, etal., Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3890-6. Epub 2009 Apr 8.
56. Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7). Marchetti G, etal., Hum Genet. 1992 Jul;89(5):497-502.
57. Vitamin K-reversible hypoprothrombinemia in rats: comparison of hypoprothrombinemic changes in various strains of rats caused by vitamin K deficiency and antibiotic treatment. Matsuura M, etal., J Toxicol Sci. 1989 Aug;14(3):165-80.
58. Vitamin K-reversible hypoprothrombinemia in rats. I. Sex differences in the development of hypoprothrombinemia and the effects of beta-lactam antibiotics. Matsuura M, etal., Jpn J Pharmacol. 1988 Mar;46(3):303-10.
59. [Expression of fusion protein encoding EGFP-EGF1 of rat coagulation factor VII and its binding function] May H, etal., Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):181-4.
60. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
61. Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves blood coagulation abnormalities and dysfunction of vascular endothelial cells in Otsuka Long-Evans Tokushima fatty rats. Mori Y, etal., Endocr J. 2003 Oct;50(5):603-11.
62. Hypercoagulable state in a hypobaric, hypoxic environment causes non-bacterial thrombotic endocarditis in rats. Nakanishi K, etal., J Pathol. 1997 Mar;181(3):338-46.
63. Somatotropin and somatostatin effects on vitamin K-dependent plasma coagulation factors. Negrev N, etal., Eur J Pharmacol. 1995 Apr 24;277(2-3):145-9.
64. Hormones of hypothalamic-pituitary-thyroid axis are significant regulators of synthesis and secretion of vitamin K-dependent plasma coagulation factors. Negrev N, etal., J Biol Regul Homeost Agents. 2011 Jan-Mar;25(1):21-6.
65. Effects of the hormones of the thyroid axis on the vitamin K-dependent plasma factors of blood coagulation (II, VII, IX, and X). Negrev NN, etal., Int J Immunopathol Pharmacol. 2008 Jan-Mar;21(1):221-6.
66. Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats. Nobukata H, etal., Metabolism. 2000 Jul;49(7):912-9.
67. Age-related changes in coagulation, fibrinolysis, and platelet aggregation in male WBN/Kob rats. Nobukata H, etal., Thromb Res. 2000 Jun 15;98(6):507-16.
68. Effect of dienogest on bleeding time, coagulation, fibrinolysis, and platelet aggregation in female rats. Nobukata H, etal., Toxicol Lett. 1999 Jan 11;104(1-2):93-101.
69. Blood coagulation. Norris LA, Best Pract Res Clin Obstet Gynaecol. 2003 Jun;17(3):369-83.
70. Anticoagulant modulation of blood cells and platelet reactivity by garlic oil in experimental diabetes mellitus. Ohaeri OC and Adoga GI, Biosci Rep. 2006 Feb;26(1):1-6.
71. Effects of pregnancy and lactation on warfarin-induced changes in blood coagulation-related parameters in rats. Ohishi T, etal., J Toxicol Sci. 2010 Apr;35(2):189-96.
72. A high fat meal activates blood coagulation factor VII in rats. Olsen AK, etal., J Nutr. 2002 Mar;132(3):347-50.
73. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
74. Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study. Onody A, etal., FEBS Lett. 2003 Feb 11;536(1-3):35-40.
75. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Ossei-Gerning N, etal., Thromb Haemost. 1998 Apr;79(4):736-40.
76. Initial inhibition of tissue factor signalling reduces chronic vascular changes in isogenic rat aortic transplants. Osterholm C, etal., Am J Transplant. 2001 May;1(1):29-37.
77. Joint effect of G1691A factor V point mutation and factor VII Arg/Gln(353) gene polymorphism on the risk of premature coronary artery disease. Petrovic D, etal., Ann Genet. 2001 Jan-Mar;44(1):33-6.
78. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
79. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
80. Health effects of subchronic exposure to environmental levels of diesel exhaust. Reed MD, etal., Inhal Toxicol. 2004 Apr;16(4):177-93.
81. GOA pipeline RGD automated data pipeline
82. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
83. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
84. Comprehensive gene review and curation RGD comprehensive gene curation
85. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Rosen ED, etal., Nature 1997 Nov 20;390(6657):290-4.
86. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Scharrer I Haemophilia. 1999 Jul;5(4):253-9.
87. Recombinant activated coagulation factor VII and prothrombin complex concentrates are equally effective in reducing hematoma volume in experimental warfarin-associated intracerebral hemorrhage. Schlunk F, etal., Stroke. 2012 Jan;43(1):246-9. doi: 10.1161/STROKEAHA.111.629360. Epub 2011 Oct 13.
88. Cloning and expression of rat coagulation factor VII. Seetharam S, etal., Thromb Res. 2003 Feb 15;109(4):225-31.
89. The Effect of Carbon Dioxide Insufflation Applied at Different Pressures and Periods on Thrombotic Factors. Sen MC, etal., Indian J Hematol Blood Transfus. 2016 Mar;32(1):87-91. doi: 10.1007/s12288-015-0517-2. Epub 2015 Feb 15.
90. How it all starts: Initiation of the clotting cascade. Smith SA, etal., Crit Rev Biochem Mol Biol. 2015;50(4):326-36. doi: 10.3109/10409238.2015.1050550. Epub 2015 May 28.
91. Circadian rhythms of blood clotting time and coagulation factors II, VII, IX and X in rats. Soulban G and Labrecque G, Life Sci. 1989;45(25):2485-9.
92. Active site-inactivated factor VIIa inhibits nuclear factor kappa B activation in intestinal ischemia and reperfusion. Stollenwerk MM, etal., J Surg Res. 2012 Dec;178(2):692-9. doi: 10.1016/j.jss.2012.07.056. Epub 2012 Aug 10.
93. Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. Szalony JA, etal., J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
94. Extrahepatic synthesis of coagulation factor VII by colorectal cancer cells promotes tumor invasion and metastasis. Tang JQ, etal., Chin Med J (Engl). 2010 Dec;123(24):3559-65.
95. Blood coagulation changes in rats during development of epithelioma. Tomasiuk R, etal., Neoplasma. 1989;36(2):179-84.
96. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Vambergue A, etal., Thromb Res. 2001 Mar 1;101(5):367-75.
97. The influence of the thyroid function on the metabolic rate of prothrombin, factor VII, and factor X in the rat. van Oosterom AT, etal., Thromb Haemost. 1976 Jun 30;35(3):607-19.
98. A chromogenic assay for coagulation factor VII: analytical performance characteristics and application in several diseases. van Wersch JW Int J Clin Lab Res. 1993;23(4):221-4.
99. Preferential consumption of coagulation factors I, V, and VIII in rat endotoxemia. Yamaguchi K, etal., Shock. 2000 Nov;14(5):535-43.
100. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Yokota N, etal., Br J Cancer. 2009 Dec 15;101(12):2023-9. doi: 10.1038/sj.bjc.6605406. Epub 2009 Nov 10.
101. Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer. Zerbib P, etal., J Surg Res. 2009 May 15;153(2):239-45. doi: 10.1016/j.jss.2008.05.014. Epub 2008 Jun 11.
Additional References at PubMed
PMID:8632006   PMID:17991872   PMID:18612547   PMID:24998411  


Genomics

Comparative Map Data
F7
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81683,191,896 - 83,202,775 (-)NCBIGRCr8
mRatBN7.21676,489,775 - 76,500,636 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1676,489,717 - 76,500,610 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1681,770,823 - 81,781,136 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01685,223,400 - 85,233,713 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01680,472,689 - 80,483,066 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01681,824,610 - 81,834,923 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1681,824,111 - 81,834,945 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01681,309,476 - 81,320,833 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41681,348,678 - 81,358,991 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11681,348,942 - 81,359,256 (-)NCBI
Celera1674,296,307 - 74,306,282 (-)NCBICelera
Cytogenetic Map16q12.5NCBI
F7
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh3813113,105,788 - 113,120,685 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl13113,105,788 - 113,120,685 (+)EnsemblGRCh38hg38GRCh38
GRCh3713113,760,102 - 113,774,999 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 3613112,808,106 - 112,822,996 (+)NCBINCBI36Build 36hg18NCBI36
Build 3413112,808,105 - 112,822,346NCBI
Celera1394,585,687 - 94,600,980 (+)NCBICelera
Cytogenetic Map13q34NCBI
HuRef1394,198,534 - 94,213,700 (+)NCBIHuRef
CHM1_113113,728,824 - 113,743,117 (+)NCBICHM1_1
T2T-CHM13v2.013112,357,141 - 112,372,343 (+)NCBIT2T-CHM13v2.0
F7
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39813,075,499 - 13,085,809 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl813,076,034 - 13,085,809 (+)EnsemblGRCm39 Ensembl
GRCm38813,025,506 - 13,035,809 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl813,026,034 - 13,035,809 (+)EnsemblGRCm38mm10GRCm38
MGSCv37813,026,034 - 13,035,809 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36813,026,023 - 13,035,786 (+)NCBIMGSCv36mm8
Celera813,193,833 - 13,203,593 (+)NCBICelera
Cytogenetic Map8A1.1NCBI
cM Map85.73NCBI
F7
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_004955404680,594 - 693,665 (-)EnsemblChiLan1.0
ChiLan1.0NW_004955404685,170 - 692,797 (-)NCBIChiLan1.0ChiLan1.0
F7
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v214114,609,021 - 114,625,255 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan113113,294,521 - 113,308,050 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01394,246,694 - 94,261,133 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.113113,315,868 - 113,329,995 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl13113,315,868 - 113,329,995 (+)Ensemblpanpan1.1panPan2
F7
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.12260,572,459 - 60,582,743 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2260,571,822 - 60,597,024 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha2260,285,105 - 60,295,147 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.02261,197,920 - 61,208,435 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl2261,197,839 - 61,208,421 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.12260,696,588 - 60,706,712 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.02260,698,754 - 60,708,987 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.02260,729,611 - 60,740,074 (+)NCBIUU_Cfam_GSD_1.0
F7
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024404945195,436,780 - 195,446,532 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_004936472505,751 - 514,339 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_004936472505,751 - 515,375 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
F7
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1178,512,137 - 78,518,668 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11178,512,389 - 78,518,668 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21186,217,112 - 86,223,394 (-)NCBISscrofa10.2Sscrofa10.2susScr3
F7
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1391,109,864 - 91,122,707 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl391,110,380 - 91,123,327 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366604648,125,875 - 48,139,708 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
F7
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_004624793780,059 - 788,095 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_004624793780,057 - 788,105 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in F7
15 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:95
Count of miRNA genes:88
Interacting mature miRNAs:93
Transcripts:ENSRNOT00000037806
Prediction methods:Microtar, Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1600378Arunc4Aerobic running capacity QTL 40.03exercise endurance trait (VT:0002332)maximum distance run on treadmill (CMO:0001406)1638024580345693Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor depth of invasion (CMO:0001888)161769679182635055Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor depth of invasion (CMO:0001888)161769679182635055Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor diameter (CMO:0001889)161769679182635055Rat
70205Gcr3Gastric cancer resistance QTL 32.3stomach morphology trait (VT:0000470)stomach tumor diameter (CMO:0001889)161769679182635055Rat
1578768Stresp22Stress response QTL 222.8thymus mass (VT:0004954)thymus wet weight (CMO:0000855)163528887080288870Rat
2293690Bss45Bone structure and strength QTL 455.130.0001lumbar vertebra morphology trait (VT:0010494)lumbar vertebra cortical cross-sectional area (CMO:0001690)163775215682752156Rat
2300163Bmd64Bone mineral density QTL 645.30.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)163775215682752156Rat
7205510Activ5Activity QTL 53.780.00028locomotor behavior trait (VT:0001392)number of entries into a discrete space in an experimental apparatus (CMO:0000960)164239634584729064Rat
8694429Bw164Body weight QTL 16450.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)165272646484729064Rat
8694364Abfw7Abdominal fat weight QTL 712.220.001visceral adipose mass (VT:0010063)abdominal fat pad weight to body weight ratio (CMO:0000095)165272646484729064Rat
7411648Foco22Food consumption QTL 22150.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)165272646484729064Rat
631525Pia14Pristane induced arthritis QTL 144.4joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)165571108783402471Rat


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 23 23 23
Low 2 22 18 13 18 1 1 5 2 1
Below cutoff 7 12 6 3 3 8 22 30 7 3

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000037806   ⟹   ENSRNOP00000038466
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1676,489,717 - 76,500,610 (-)Ensembl
Rnor_6.0 Ensembl1681,824,111 - 81,834,945 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000109789   ⟹   ENSRNOP00000095256
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1676,489,717 - 76,498,532 (-)Ensembl
RefSeq Acc Id: NM_152846   ⟹   NP_690059
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81683,191,914 - 83,202,738 (-)NCBI
mRatBN7.21676,489,775 - 76,500,599 (-)NCBI
Rnor_6.01681,824,610 - 81,834,923 (-)NCBI
Rnor_5.01681,309,476 - 81,320,833 (-)NCBI
RGSC_v3.41681,348,678 - 81,358,991 (-)RGD
Celera1674,296,307 - 74,306,282 (-)RGD
Sequence:
RefSeq Acc Id: XM_039094239   ⟹   XP_038950167
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81683,191,896 - 83,202,775 (-)NCBI
mRatBN7.21676,489,779 - 76,500,636 (-)NCBI
RefSeq Acc Id: XM_039094240   ⟹   XP_038950168
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81683,191,896 - 83,202,769 (-)NCBI
mRatBN7.21676,490,589 - 76,500,630 (-)NCBI
RefSeq Acc Id: XM_039094241   ⟹   XP_038950169
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81683,191,896 - 83,202,769 (-)NCBI
mRatBN7.21676,490,589 - 76,500,630 (-)NCBI
Reference Protein Sequences
RefSeq Acc Id: NP_690059   ⟸   NM_152846
- Peptide Label: precursor
- UniProtKB: Q8K3U6 (UniProtKB/Swiss-Prot),   A6IWK3 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000038466   ⟸   ENSRNOT00000037806
RefSeq Acc Id: XP_038950167   ⟸   XM_039094239
- Peptide Label: isoform X1
- UniProtKB: A6IWK3 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038950169   ⟸   XM_039094241
- Peptide Label: isoform X3
RefSeq Acc Id: XP_038950168   ⟸   XM_039094240
- Peptide Label: isoform X2
RefSeq Acc Id: ENSRNOP00000095256   ⟸   ENSRNOT00000109789
Protein Domains
EGF-like   Gla   Peptidase S1

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q8K3U6-F1-model_v2 AlphaFold Q8K3U6 1-446 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13700237
Promoter ID:EPDNEW_R10760
Type:multiple initiation site
Name:F7_1
Description:coagulation factor VII
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01681,834,932 - 81,834,992EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:628678 AgrOrtholog
BioCyc Gene G2FUF-10696 BioCyc
Ensembl Genes ENSRNOG00000032737 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  ENSRNOG00055015036 UniProtKB/Swiss-Prot
  ENSRNOG00060019172 UniProtKB/Swiss-Prot
  ENSRNOG00065009327 UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000037806 ENTREZGENE
  ENSRNOT00000037806.3 UniProtKB/Swiss-Prot
  ENSRNOT00000109789.1 UniProtKB/TrEMBL
  ENSRNOT00055025721 UniProtKB/Swiss-Prot
  ENSRNOT00060033261 UniProtKB/Swiss-Prot
  ENSRNOT00065014914 UniProtKB/Swiss-Prot
Gene3D-CATH 2.40.10.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  4.10.740.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Laminin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Coagulation_fac-like_Gla_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF-like_Ca-bd_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF-like_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF-type_Asp/Asn_hydroxyl_site UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_Ca-bd_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GLA-like_dom_SF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GLA_domain UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Pept_S1A_FX UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1_PA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1_PA_chymotrypsin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1A UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Trypsin_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_HIS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_SER UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:260320 UniProtKB/Swiss-Prot
NCBI Gene 260320 ENTREZGENE
PANTHER COAGULATION FACTOR UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR24278:SF26 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam EGF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  FXa_inhibition UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Gla UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Trypsin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PharmGKB F7 RGD
PhenoGen F7 PhenoGen
PIRSF Factor_X UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PRINTS CHYMOTRYPSIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGFBLOOD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GLABLOOD UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE ASX_HYDROXYL UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_CA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GLA_1 UniProtKB/Swiss-Prot
  GLA_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_DOM UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_HIS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_SER UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000032737 RatGTEx
  ENSRNOG00055015036 RatGTEx
  ENSRNOG00060019172 RatGTEx
  ENSRNOG00065009327 RatGTEx
SMART EGF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_CA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  GLA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tryp_SPc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP EGF/Laminin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF50494 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF57630 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A8I6ANC9_RAT UniProtKB/TrEMBL
  A6IWK3 ENTREZGENE, UniProtKB/TrEMBL
  A6IWK4_RAT UniProtKB/TrEMBL
  A6IWK5_RAT UniProtKB/TrEMBL
  FA7_RAT UniProtKB/Swiss-Prot, ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2016-01-20 F7  coagulation factor VII  F7  coagulation factor VII (serum prothrombin conversion accelerator)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-10-17 F7  coagulation factor VII (serum prothrombin conversion accelerator)  F7  coagulation factor VII  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2005-01-20 F7  coagulation factor VII      Symbol and Name status set to approved 1299863 APPROVED
2003-02-27 F7  coagulation factor VII      Symbol and Name status set to provisional 70820 PROVISIONAL